429 related articles for article (PubMed ID: 28423178)
1. Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury.
Reichetzeder C; von Websky K; Tsuprykov O; Mohagheghi Samarin A; Falke LG; Dwi Putra SE; Hasan AA; Antonenko V; Curato C; Rippmann J; Klein T; Hocher B
Br J Pharmacol; 2017 Jul; 174(14):2273-2286. PubMed ID: 28423178
[TBL] [Abstract][Full Text] [Related]
2. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
[TBL] [Abstract][Full Text] [Related]
3. DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury.
Glorie LL; Verhulst A; Matheeussen V; Baerts L; Magielse J; Hermans N; D'Haese PC; De Meester I; De Beuf A
Am J Physiol Renal Physiol; 2012 Sep; 303(5):F681-8. PubMed ID: 22718884
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.
Hausenloy DJ; Whittington HJ; Wynne AM; Begum SS; Theodorou L; Riksen N; Mocanu MM; Yellon DM
Cardiovasc Diabetol; 2013 Oct; 12():154. PubMed ID: 24148218
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase 4 inhibitor reduces intimal hyperplasia in rabbit autologous jugular vein graft under poor distal runoff.
Koyama A; Komori K; Otsuka R; Kajikuri J; Itoh T
J Vasc Surg; 2016 May; 63(5):1360-70. PubMed ID: 25656593
[TBL] [Abstract][Full Text] [Related]
6. Effects of linagliptin on human immortalized podocytes: a cellular system to study dipeptidyl-peptidase 4 inhibition.
Miglio G; Vitarelli G; Klein T; Benetti E
Br J Pharmacol; 2017 May; 174(9):809-821. PubMed ID: 28177527
[TBL] [Abstract][Full Text] [Related]
7. Establishment of a dipeptidyl peptidases (DPP) 8/9 expressing cell model for evaluating the selectivity of DPP4 inhibitors.
Huan Y; Jiang Q; Liu JL; Shen ZF
J Pharmacol Toxicol Methods; 2015; 71():8-12. PubMed ID: 25464020
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of renovascular damage in Zucker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE- and DPP4-inhibitory Activity.
Wang Y; Landheer S; van Gilst WH; van Amerongen A; Hammes HP; Henning RH; Deelman LE; Buikema H
PLoS One; 2012; 7(10):e46781. PubMed ID: 23071636
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.
Edgerton DS; Johnson KM; Neal DW; Scott M; Hobbs CH; Zhang X; Duttaroy A; Cherrington AD
Diabetes; 2009 Jan; 58(1):243-9. PubMed ID: 18840785
[TBL] [Abstract][Full Text] [Related]
10. Reno-protective effect of linagliptin against gentamycin nephrotoxicity in rats.
Helmy MM; Mouneir SM
Pharmacol Rep; 2019 Dec; 71(6):1133-1139. PubMed ID: 31675669
[TBL] [Abstract][Full Text] [Related]
11. Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.
He YL; Valencia J; Zhang Y; Schwartz SL; Ligueros-Saylan M; Foley J; Dole WP
Br J Clin Pharmacol; 2010 Jul; 70(1):34-42. PubMed ID: 20642545
[TBL] [Abstract][Full Text] [Related]
12. Urinary DPP4 correlates with renal dysfunction, and DPP4 inhibition protects against the reduction in megalin and podocin expression in experimental CKD.
Benetti A; Martins FL; Sene LB; Shimizu MHM; Seguro AC; Luchi WM; Girardi ACC
Am J Physiol Renal Physiol; 2021 Mar; 320(3):F285-F296. PubMed ID: 33346727
[TBL] [Abstract][Full Text] [Related]
13. Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.
Wang A; Dorso C; Kopcho L; Locke G; Langish R; Harstad E; Shipkova P; Marcinkeviciene J; Hamann L; Kirby MS
BMC Pharmacol; 2012 Apr; 12():2. PubMed ID: 22475049
[TBL] [Abstract][Full Text] [Related]
14. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.
Liu X; Men P; Wang Y; Zhai S; Liu G
Lipids Health Dis; 2016 Nov; 15(1):204. PubMed ID: 27881129
[TBL] [Abstract][Full Text] [Related]
15. Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptin.
Luippold G; Mark M; Klein T; Amann K; Daniel C
Diabetes Res Clin Pract; 2018 Sep; 143():199-203. PubMed ID: 30031047
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
Liu WJ; Xie SH; Liu YN; Kim W; Jin HY; Park SK; Shao YM; Park TS
J Pharmacol Exp Ther; 2012 Feb; 340(2):248-55. PubMed ID: 22025647
[TBL] [Abstract][Full Text] [Related]
17. Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice.
Tebboth A; Lee S; Scowcroft A; Bingham-Gardiner P; Spencer W; Bolodeoku J; Hassan SW
Clin Ther; 2016 Aug; 38(8):1825-1832.e15. PubMed ID: 27491279
[TBL] [Abstract][Full Text] [Related]
18. Citrus bioflavonoids dipeptidyl peptidase-4 inhibition compared with gliptin antidiabetic medications.
Gupta A; Jacobson GA; Burgess JR; Jelinek HF; Nichols DS; Narkowicz CK; Al-Aubaidy HA
Biochem Biophys Res Commun; 2018 Sep; 503(1):21-25. PubMed ID: 29698678
[TBL] [Abstract][Full Text] [Related]
19. Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.
Sakai M; Uchii M; Myojo K; Kitayama T; Kunori S
Eur J Pharmacol; 2015 Aug; 761():109-15. PubMed ID: 25936515
[TBL] [Abstract][Full Text] [Related]
20. Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease.
Huang H; Shetty S; Bauer E; Lang K
Curr Med Res Opin; 2018 Jun; 34(6):1021-1027. PubMed ID: 29231750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
